BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30902694)

  • 1. Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma.
    Hayashi K; Yoshida M; Sato T; Manabe SI
    Am J Ophthalmol; 2019 Sep; 205():91-98. PubMed ID: 30902694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma.
    Holló G; Chiselita D; Petkova N; Cvenkel B; Liehneova I; Izgi B; Berta A; Szaflik J; Turacli E; Stewart WC
    Eur J Ophthalmol; 2006; 16(6):816-23. PubMed ID: 17191187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Effect of Oral Acetazolamide against Intraocular Pressure Elevation after Cataract Surgery in Eyes with Glaucoma.
    Hayashi K; Yoshida M; Manabe SI; Yoshimura K
    Ophthalmology; 2017 May; 124(5):701-708. PubMed ID: 28110949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical control of intraocular pressure with brinzolamide 1% after phacoemulsification.
    Kir E; Cakmak H; Dayanir V
    Can J Ophthalmol; 2008 Oct; 43(5):559-62. PubMed ID: 18982032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.
    Goldberg I; Crowston JG; Jasek MC; Stewart JA; Stewart WC;
    J Glaucoma; 2012 Jan; 21(1):55-9. PubMed ID: 21048504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraocular pressure elevation within the first 24 hours after cataract surgery in patients with glaucoma or exfoliation syndrome.
    Levkovitch-Verbin H; Habot-Wilner Z; Burla N; Melamed S; Goldenfeld M; Bar-Sela SM; Sachs D
    Ophthalmology; 2008 Jan; 115(1):104-8. PubMed ID: 17561259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antiglaucoma agents on postoperative intraocular pressure after cataract surgery with Viscoat.
    Borazan M; Karalezli A; Akman A; Akova YA
    J Cataract Refract Surg; 2007 Nov; 33(11):1941-5. PubMed ID: 17964402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of topical brinzolamide 1% and brimonidine 0.2% on intraocular pressure after phacoemulsification.
    Cetinkaya A; Akman A; Akova YA
    J Cataract Refract Surg; 2004 Aug; 30(8):1736-41. PubMed ID: 15313300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brinzolamide-timolol fixed combination for the prevention of intraocular pressure elevation after phacoemulsification.
    Georgakopoulos CD; Makri OE; Plotas P; Pharmakakis N
    Clin Exp Ophthalmol; 2013; 41(7):662-7. PubMed ID: 23432730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy.
    Shin D
    Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S163-8. PubMed ID: 10665519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical control of intraocular pressure after phacoemulsification.
    Dayanir V; Ozcura F; Kir E; Topaloğlu A; Ozkan SB; Aktunç T
    J Cataract Refract Surg; 2005 Mar; 31(3):484-8. PubMed ID: 15811735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma.
    Holló G; Kóthy P
    Curr Med Res Opin; 2008 Jun; 24(6):1755-61. PubMed ID: 18479590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre.
    Kóthy P; Holló G
    Int Ophthalmol; 2020 Feb; 40(2):377-383. PubMed ID: 31650353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
    Silver LH
    Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension.
    Pfeiffer N;
    Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):1065-71. PubMed ID: 21499770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%.
    Kaback M; Scoper SV; Arzeno G; James JE; Hua SY; Salem C; Dickerson JE; Landry TA; Bergamini MV;
    Ophthalmology; 2008 Oct; 115(10):1728-34, 1734.e1-2. PubMed ID: 18538406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.